Candonilimab

Generic Name: Candonilimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2394841-59-7

Unique Ingredient Identifier: 6FYG1DS4NW

Background: Cadonilimab is under investigation in clinical trial NCT04220307 (A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma).

Indication: 用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌患者的治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Phase 2

Not yet recruiting

Conditions: Endometrial Cancer
Endometrial Adenocarcinoma

Interventions: Drug: Cadonilimab
Drug: Lenvatinib

First Posted Date: 2023-04-21

Last Posted Date: 2023-04-21

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 32

Registration Number: NCT05824481

Locations: 🇨🇳
Sun Yat-sen University Cancer Cetntre, Guangzhou, China

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

Phase 2

Recruiting

Conditions: Cervical Cancer

Interventions: Drug: Cadonilimab
Drug: Anlotinib
Drug: Granulocyte-Macrophage Colony-Stimulating Factor

First Posted Date: 2023-04-18

Last Posted Date: 2024-04-19

Lead Sponsor: Zhongnan Hospital

Target Recruit Count: 35

Registration Number: NCT05817214

Locations: 🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 1

Active, not recruiting

Conditions: NSCLC Stage IV
NSCLC Stage IIIB
NSCLC Stage IIIC

Interventions: Drug: Cadonilimab
Drug: Anlotinib
Drug: Docetaxel

First Posted Date: 2023-04-18

Last Posted Date: 2024-06-17

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 50

Registration Number: NCT05816499

Locations: 🇨🇳
lejie Cao, Hefei, Anhui, China
🇨🇳
Jing Wang, Qingdao, Shandong, China
🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

and more 2 locations

XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer

Phase 2

Recruiting

Conditions: Rectal Cancer
MSS

Interventions: Drug: Cadonilimab
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2023-04-18

Last Posted Date: 2023-04-18

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 92

Registration Number: NCT05815303

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer

Phase 2

Recruiting

Conditions: dMMR Colorectal Cancer

Interventions: Drug: Cadonilimab

First Posted Date: 2023-04-18

Last Posted Date: 2023-04-18

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 50

Registration Number: NCT05815290

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases

Phase 2

Not yet recruiting

Conditions: Brain Metastases
Non Small Cell Lung Cancer

Interventions: Drug: Cadonilimab

First Posted Date: 2023-04-13

Last Posted Date: 2023-11-18

Lead Sponsor: Second Affiliated Hospital of Nanchang University

Target Recruit Count: 36

Registration Number: NCT05812534

A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

Phase 1

Not yet recruiting

Conditions: Renal Cell Carcinoma
Non Clear Cell Renal Cell Carcinoma
First-line Treatment
Sarcomatoid Renal Cell Carcinoma

Interventions: Drug: AK104
Drug: Axitinib

First Posted Date: 2023-04-11

Last Posted Date: 2023-09-25

Lead Sponsor: Hao Zeng

Target Recruit Count: 33

Registration Number: NCT05808608

Locations: 🇨🇳
West China Hospital, Chengdu, Sichuan, China

Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma

Phase 2

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Cadonilimab

First Posted Date: 2023-03-30

Last Posted Date: 2023-03-30

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 30

Registration Number: NCT05790200

Locations: 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer

Phase 2

Not yet recruiting

Conditions: Lung Cancer

Interventions: Drug: Cadonilimab

First Posted Date: 2023-03-27

Last Posted Date: 2023-03-27

Lead Sponsor: The First Hospital of Jilin University

Target Recruit Count: 37

Registration Number: NCT05784974

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Candonilimab
Drug: Bevacizumab

First Posted Date: 2023-03-08

Last Posted Date: 2023-03-08

Lead Sponsor: Shi Ming

Target Recruit Count: 30

Registration Number: NCT05760599

Locations: 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy